UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 38

Sortiert nach

Physiologically‐Based Pharmacokinetic Modeling in Renal and Hepatic Impairment Populations: A Pharmaceutical Industry Perspective

Clinical pharmacology and therapeutics, 2021-08, Vol.110 (2), p.297-310

2021

Volltextzugriff (PDF)

Recommendations for the Design of Clinical Drug–Drug Interaction Studies With Itraconazole Using a Mechanistic Physiologically‐Based Pharmacokinetic Model

CPT: pharmacometrics and systems pharmacology, 2019-09, Vol.8 (9), p.685-695

2019

Volltextzugriff (PDF)

Genetic and phenotypic variation in UGT2B17, a testosterone-metabolizing enzyme, is associated with BMI in males

Pharmacogenetics and genomics, 2015-05, Vol.25 (5), p.263-269

2015

Volltextzugriff (PDF)

Novel CYP2A6 variants identified in African Americans are associated with slow nicotine metabolism in vitro and in vivo

Pharmacogenetics and genomics, 2014-02, Vol.24 (2), p.118-128

2014

Volltextzugriff (PDF)

Functional characterization of novel rare CYP2A6 variants and potential implications for clinical outcomes

Clinical and translational science, 2022-01, Vol.15 (1), p.204-220

2022

Volltextzugriff (PDF)

CYP2A6 and CYP2B6 genetic variation and its association with nicotine metabolism in South Western Alaska Native people

Pharmacogenetics and genomics, 2012-06, Vol.22 (6), p.429-440

2012

Volltextzugriff (PDF)

A Citrulline‐Based Translational Population System Toxicology Model for Gastrointestinal‐Related Adverse Events Associated With Anticancer Treatments

CPT: pharmacometrics and systems pharmacology, 2019-12, Vol.8 (12), p.951-961

2019

Volltextzugriff (PDF)

Variation in P450 oxidoreductase (POR) A503V and flavin-containing monooxygenase (FMO)-3 E158K is associated with minor alterations in nicotine metabolism, but does not alter cigarette consumption

Pharmacogenetics and genomics, 2014-03, Vol.24 (3), p.172-176

2014

Volltextzugriff (PDF)

Pharmacogenetics of Drug Dependence: Role of Gene Variations in Susceptibility and Treatment

Annual review of pharmacology and toxicology, 2010-02, Vol.50 (1), p.39-61

2010

Volltextzugriff (PDF)

Applications of Quantitative System Pharmacology Modeling to Model-Informed Drug Development

Methods in molecular biology (Clifton, N.J.), 2022, Vol.2486, p.71

2022

Volltextzugriff (PDF)

A Minimal Physiologically‐Based Pharmacokinetic Model Demonstrates Role of the Neonatal Fc Receptor (FcRn) Competition in Drug–Disease Interactions With Antibody Therapy

Clinical pharmacology and therapeutics, 2020-02, Vol.107 (2), p.423-434

2020

Volltextzugriff (PDF)

Leveraging a physiologically-based quantitative translational modeling platform for designing B cell maturation antigen-targeting bispecific T cell engagers for treatment of multiple myeloma

PLoS computational biology, 2022-07, Vol.18 (7), p.e1009715-e1009715

2022

Volltextzugriff (PDF)

Quantitative Systems Pharmacology Approaches for Immuno‐Oncology: Adding Virtual Patients to the Development Paradigm

Clinical pharmacology and therapeutics, 2021-03, Vol.109 (3), p.605-618

2021

Volltextzugriff (PDF)

Effects of Menthol on Nicotine Pharmacokinetic, Pharmacology and Dependence in Mice

PloS one, 2015-09, Vol.10 (9), p.e0137070

2015

Volltextzugriff (PDF)

A quantitative systems pharmacology model of plasma kallikrein-kinin system dysregulation in hereditary angioedema

Journal of pharmacokinetics and pharmacodynamics, 2024-05

2024

Volltextzugriff (PDF)

Does sex alter the relationship between CYP2B6 variation, hydroxybupropion concentration and bupropion‐aided smoking cessation in African Americans? A moderated mediation analysis

Addiction (Abingdon, England), 2022-06, Vol.117 (6), p.1715-1724

2022

Volltextzugriff (PDF)

The Ability of Plasma Cotinine to Predict Nicotine and Carcinogen Exposure is Altered by Differences in CYP2A6: the Influence of Genetics, Race, and Sex

Cancer epidemiology, biomarkers & prevention, 2013-04, Vol.22 (4), p.708-718

2013

Volltextzugriff (PDF)

Genome‐wide association study of a nicotine metabolism biomarker in African American smokers: impact of chromosome 19 genetic influences

Addiction (Abingdon, England), 2018-03, Vol.113 (3), p.509-523

2018

Volltextzugriff (PDF)

Influence of CYP2B6 genetic variants on plasma and urine concentrations of bupropion and metabolites at steady state

Pharmacogenetics and genomics, 2013-03, Vol.23 (3), p.135-141

2013

Volltextzugriff (PDF)

CYP2B6 and Bupropion's Smoking-Cessation Pharmacology: The Role of Hydroxybupropion

Clinical pharmacology and therapeutics, 2012-12, Vol.92 (6), p.771-777

2012

Volltextzugriff (PDF)

Variation in trans-3'-hydroxycotinine glucuronidation does not alter the nicotine metabolite ratio or nicotine intake

PloS one, 2013-08, Vol.8 (8), p.e70938

2013

Volltextzugriff (PDF)

Association of CHRNA5-A3-B4 SNP rs2036527 With Smoking Cessation Therapy Response in African-American Smokers

Clinical pharmacology and therapeutics, 2014-08, Vol.96 (2), p.256-265

2014

Volltextzugriff (PDF)

Application of unbound liver-to-plasma concentration ratio to quantitative projection of cytochrome P450-mediated drug-drug interactions using physiologically based pharmacokinetic modelling approach

Xenobiotica, 2019-11, Vol.49 (11), p.1251-1259

2019

Volltextzugriff (PDF)

Effects of methoxsalen, a CYP2A5/6 inhibitor, on nicotine dependence behaviors in mice

Neuropharmacology, 2014-10, Vol.85, p.67-72

2014

Volltextzugriff (PDF)

Lack of Associations of CHRNA5-A3-B4 Genetic Variants with Smoking Cessation Treatment Outcomes in Caucasian Smokers despite Associations with Baseline Smoking

PloS one, 2015-05, Vol.10 (5), p.e0128109

2015

Volltextzugriff (PDF)

1 – 25 von 38

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(35)
Mit Volltextzugriff
(34)

Publikationsform

Artikel
(36)
Buchkapitel
(2)

Sprache

Englisch
(38)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Physiologically‐Based Pharmacokinetic Modeling in Renal and Hepatic Impairment Populations: A Pharmaceutical Industry Perspective

Recommendations for the Design of Clinical Drug–Drug Interaction Studies With Itraconazole Using a Mechanistic Physiologically‐Based Pharmacokinetic Model

Genetic and phenotypic variation in UGT2B17, a testosterone-metabolizing enzyme, is associated with BMI in males

Novel CYP2A6 variants identified in African Americans are associated with slow nicotine metabolism in vitro and in vivo

Functional characterization of novel rare CYP2A6 variants and potential implications for clinical outcomes

CYP2A6 and CYP2B6 genetic variation and its association with nicotine metabolism in South Western Alaska Native people

A Citrulline‐Based Translational Population System Toxicology Model for Gastrointestinal‐Related Adverse Events Associated With Anticancer Treatments

Variation in P450 oxidoreductase (POR) A503V and flavin-containing monooxygenase (FMO)-3 E158K is associated with minor alterations in nicotine metabolism, but does not alter cigarette consumption

Pharmacogenetics of Drug Dependence: Role of Gene Variations in Susceptibility and Treatment

Applications of Quantitative System Pharmacology Modeling to Model-Informed Drug Development

A Minimal Physiologically‐Based Pharmacokinetic Model Demonstrates Role of the Neonatal Fc Receptor (FcRn) Competition in Drug–Disease Interactions With Antibody Therapy

Leveraging a physiologically-based quantitative translational modeling platform for designing B cell maturation antigen-targeting bispecific T cell engagers for treatment of multiple myeloma

Quantitative Systems Pharmacology Approaches for Immuno‐Oncology: Adding Virtual Patients to the Development Paradigm

Effects of Menthol on Nicotine Pharmacokinetic, Pharmacology and Dependence in Mice

A quantitative systems pharmacology model of plasma kallikrein-kinin system dysregulation in hereditary angioedema

Does sex alter the relationship between CYP2B6 variation, hydroxybupropion concentration and bupropion‐aided smoking cessation in African Americans? A moderated mediation analysis

The Ability of Plasma Cotinine to Predict Nicotine and Carcinogen Exposure is Altered by Differences in CYP2A6: the Influence of Genetics, Race, and Sex

Genome‐wide association study of a nicotine metabolism biomarker in African American smokers: impact of chromosome 19 genetic influences

Influence of CYP2B6 genetic variants on plasma and urine concentrations of bupropion and metabolites at steady state

CYP2B6 and Bupropion's Smoking-Cessation Pharmacology: The Role of Hydroxybupropion

Variation in trans-3'-hydroxycotinine glucuronidation does not alter the nicotine metabolite ratio or nicotine intake

Association of CHRNA5-A3-B4 SNP rs2036527 With Smoking Cessation Therapy Response in African-American Smokers

Application of unbound liver-to-plasma concentration ratio to quantitative projection of cytochrome P450-mediated drug-drug interactions using physiologically based pharmacokinetic modelling approach

Effects of methoxsalen, a CYP2A5/6 inhibitor, on nicotine dependence behaviors in mice

Lack of Associations of CHRNA5-A3-B4 Genetic Variants with Smoking Cessation Treatment Outcomes in Caucasian Smokers despite Associations with Baseline Smoking

Suchergebnisse filtern